Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 222, Issue 12, Pages 1960-1964Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa593
Keywords
primary immunodeficiency; SARS-CoV-2; SARS coronavirus 2 antibody titer; neutralizing antibodies; COVID-19; intravenous immunoglobulin; plasma
Categories
Funding
- Baxter AG, part of the Takeda group of companies, Vienna, Austria
Ask authors/readers for more resources
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available